Telehealth's Next Multibillion-Dollar Market May Be Just Around the Corner

The world of peptides, tiny protein fragments used for recovery, energy boosts, and anti-aging, is on the cusp of a major transformation. Compounding pharmacies, which have been quietly turning peptides into a multibillion-dollar industry, may soon be given a green light by the FDA to mix and sell these substances on a larger scale. The implications are massive, with telehealth companies like Hims and Hers already positioning themselves to capitalize on this emerging market.

Background & Context

The FDA's compounding advisory committee will meet on July 23 and 24 to review seven peptides, including BPC-157 and TB-500, which have gained popularity among biohackers and those seeking to optimize their health. These substances have been sold on the gray market, with users injecting them to achieve various benefits. The FDA's decision will determine whether these peptides can be legally mixed by specialty pharmacies, paving the way for a new market.

This is not the first time the FDA has been faced with a decision that could create a multibillion-dollar industry. Two years ago, the agency's decision to allow compounding pharmacies to mix cheaper versions of Ozempic, a diabetes medication, led to a shadow industry worth billions. The FDA's current deliberation has the potential to create a similar market for wellness peptides, which are being touted as a way to slow aging and improve overall health.

Key Details

One of the companies set to benefit from the FDA's decision is Hims, a telehealth company that built a business on cheaper, pharmacy-mixed versions of Ozempic and Wegovy. The company's stock took a hit when the FDA proposed excluding these drugs from the pharmacy compounding list, but it has since diversified its offerings and is now exploring the peptide market. Hims' chief medical officer, Dr. Anant Vinjamoori, will be testifying at the FDA hearing on Thursday.

Telehealth infrastructure company Wheel CEO Michelle Davey predicts that big telehealth players will move quickly to capitalize on the peptide market once it gets the green light. Davey estimates that the addressable peptide market, including gray-market use, GLP-1 add-ons, and general health-optimization peptides, is roughly $30 billion. This is a massive opportunity for telehealth companies, which have been growing rapidly in recent years.

However, the peptide market is not without its challenges. Users often stack multiple compounds at once, which can be problematic given the lack of long-term safety data on these combinations. Most popular peptides have never gone through large, controlled human trials, and are sold as "research chemicals" outside normal drug-approval channels.

What Experts Say

Telehealth infrastructure company Wheel CEO Michelle Davey believes that the well-funded platforms will out-compete the fly-by-night operators on price and credibility, and the smaller players will either get bought or die. This is a familiar pattern, as seen in the GLP-1 market, where over 80 founders with Shopify accounts launched clinics by late 2024.

Jon Keidan, founder and managing partner of Torch Capital, which has invested in direct-to-consumer telehealth company Ro, notes that the peptide market is a natural extension of the growing interest in personalized medicine. As consumers become more aware of the potential benefits of peptides, they will increasingly turn to telehealth companies to access these substances.

Key Takeaways

• The FDA is set to review seven peptides, including BPC-157 and TB-500, which could be legally mixed by specialty pharmacies.
• Telehealth companies like Hims and Hers are positioning themselves to capitalize on the emerging peptide market.
• The peptide market is estimated to be worth around $30 billion, including gray-market use, GLP-1 add-ons, and general health-optimization peptides.
• The lack of long-term safety data on peptide combinations is a major concern, given the practice of stacking multiple compounds at once.

What This Means For You

If the FDA gives the green light to peptides, it could lead to a new market for wellness products that are touted as a way to slow aging and improve overall health. This could be a game-changer for consumers, who are increasingly interested in personalized medicine and taking control of their health.

However, it's essential to approach this new market with caution, given the lack of long-term safety data on peptide combinations. As the market grows, it's crucial to ensure that telehealth companies prioritize transparency and accountability, providing consumers with accurate information about the potential benefits and risks of peptides.

Ultimately, the emergence of the peptide market represents a significant opportunity for telehealth companies to expand their offerings and improve the lives of consumers. As the industry continues to evolve, it's essential to prioritize consumer safety and transparency, ensuring that this new market lives up to its full potential.